The Heterochronic microRNA let-7 Inhibits Cell Motility by Regulating the Genes in the Actin Cytoskeleton Pathway in Breast Cancer

The heterochronic gene let-7 serves as a tumor suppressor microRNA by targeting various oncogenic pathways in cancer cells. Considerable evidence indicates that reduced expression of let-7 might be associated with poor clinical outcome in patients with cancer. Here, we report that the expression levels of three let-7 family members, let-7a, let-7b, and let-7g, were significantly decreased in the patients with breast cancer with lymph node metastasis compared with those without lymph node metastasis. Enforced expression of let-7b significantly inhibits breast cancer cell motility and affects actin dynamics. Using bioinformatic and experimental approaches, four genes in the actin cytoskeleton pathway, including PAK1, DIAPH2, RDX, and ITGB8, were identified as let-7 direct targets. Blocking the expression of PAK1, DIAPH2, and RDX significantly inhibits breast cancer cell migration induced by let-7b repression. Our results indicate that reconstitution of let-7 expression in tumor cells could provide a novel therapeutic strategy for the treatment of metastatic disease. Mol Cancer Res; 11(3); 240–50. ©2013 AACR.

[1]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[2]  A. McClatchey.  Merlin and ERM proteins: unappreciated roles in cancer development? , 2003, Nature Reviews Cancer.

[3]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[4]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[5]  Sun-Mi Park,et al.  The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.

[6]  Chi-Hung Huang,et al.  RAC1 activation mediates Twist1-induced cancer cell migration , 2012, Nature Cell Biology.

[7]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[8]  F. Slack,et al.  Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.

[9]  Chun-Ting Lin,et al.  Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. , 2011, Experimental cell research.

[10]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[11]  D. Fan,et al.  MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer , 2011, PloS one.

[12]  Martin Reczko,et al.  DIANA-mirPath: Integrating human and mouse microRNAs in pathways , 2009, Bioinform..

[13]  M. Schwartz,et al.  Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. , 2000, Journal of cell science.

[14]  J. Melamed,et al.  Antiproliferative Effects by Let-7 Repression of High-Mobility Group A2 in Uterine Leiomyoma , 2008, Molecular Cancer Research.

[15]  S. Dangi‐Garimella,et al.  Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let‐7 , 2009, The EMBO journal.

[16]  Manfred Kunz,et al.  MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.

[17]  F. Slack,et al.  The let-7 family of microRNAs. , 2008, Trends in cell biology.

[18]  A. Bosserhoff,et al.  Integrin β3 expression is regulated by let-7a miRNA in malignant melanoma , 2008, Oncogene.

[19]  Sheng Tan,et al.  Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. , 2011, Cancer research.

[20]  T. Tominaga,et al.  mDia-interacting Protein Acts Downstream of Rho-mDia and Modifies Src Activation and Stress Fiber Formation* , 2001, The Journal of Biological Chemistry.

[21]  Xianghuo He,et al.  MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers , 2012, Oncogene.

[22]  G. Daley,et al.  Lin28: A MicroRNA Regulator with a Macro Role , 2010, Cell.

[23]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[24]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[25]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[26]  M. Mandal,et al.  Regulation of Microfilament Reorganization and Invasiveness of Breast Cancer Cells by Kinase Dead p21-activated Kinase-1* , 2000, The Journal of Biological Chemistry.

[27]  M. Cho,et al.  Suppression of A549 lung cancer cell migration by precursor let-7g microRNA. , 2010, Molecular medicine reports.

[28]  R. Weinberg,et al.  A Pleiotropically Acting Microrna, Mir-31, Inhibits Breast Cancer Metastasis Accessed Terms of Use Detailed Terms a Pleiotropically Acting Microrna, Mir-31, Inhibits Breast Cancer Metastasis , 2022 .

[29]  Hemant Ishwaran,et al.  Signalling pathway for RKIP and Let‐7 regulates and predicts metastatic breast cancer , 2011, The EMBO journal.

[30]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[31]  S. Coniglio,et al.  Pak1 and Pak2 Mediate Tumor Cell Invasion through Distinct Signaling Mechanisms , 2008, Molecular and Cellular Biology.

[32]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[33]  Y. Bae,et al.  MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7 , 2012, Breast Cancer Research.

[34]  B. Reinhart,et al.  The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans , 2000, Nature.

[35]  X. Wang,et al.  Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. , 2010, Journal of hepatology.

[36]  A. Bretscher,et al.  Organizing the cell cortex: the role of ERM proteins , 2010, Nature Reviews Molecular Cell Biology.

[37]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[38]  D. Bartel,et al.  Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs , 2004, Nature Reviews Genetics.

[39]  F. Slack,et al.  The let-7 microRNA represses cell proliferation pathways in human cells. , 2007, Cancer research.

[40]  F. Slack,et al.  let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.

[41]  S. Aizawa,et al.  Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice , 1995, Nature.

[42]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  S. Narumiya,et al.  Cdc42 and mDia3 regulate microtubule attachment to kinetochores , 2004, Nature.

[44]  J. Gu,et al.  Let‐7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer , 2012, The Journal of pathology.

[45]  Joel Greshock,et al.  Genomic DNA Copy-Number Alterations of the let-7 Family in Human Cancers , 2012, PloS one.

[46]  David P. Bartel,et al.  Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation , 2022 .

[47]  George A. Calin,et al.  MicroRNAs — the micro steering wheel of tumour metastases , 2009, Nature Reviews Cancer.

[48]  B. Reinhart,et al.  Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA , 2000, Nature.

[49]  F. Slack,et al.  The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. , 2000, Molecular cell.

[50]  John P A Ioannidis,et al.  Clinical outcome prediction by microRNAs in human cancer: a systematic review. , 2012, Journal of the National Cancer Institute.